



(51) International Patent Classification:

C07K 16/28 (2006.01) G01N 33/53 (2006.01)
A61P 29/00 (2006.01) A61M 5/00 (2006.01)

(21) International Application Number:

PCT/EP2022/060670

(22) International Filing Date:

22 April 2022 (22.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/178,745 23 April 2021 (23.04.2021) US
63/221,986 15 July 2021 (15.07.2021) US
63/270,091 21 October 2021 (21.10.2021) US

(71) Applicant: ASTRAZENECA AB [SE/SE]; SE-151 85 Södertälje (SE).

(72) Inventors: LINDHOLM, Catharina; AstraZeneca AB, SE-151 85 Södertälje (SE). CHIA, Yen Lin; AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). TUMMALA, Rajendra; AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington,


Delaware 19850-5437 (US). ROSKOS, Lorin; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). ALMQUIST, Joachim; AstraZeneca AB, SE-151 85 Södertälje (SE). ROUSE, Tomas; AstraZeneca AB, SE-151 85 Södertälje (SE). TRASIEVA, Teodora; AstraZeneca AB, SE-151 85 Södertälje (SE). WHITE, Wendy; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). SINIBALDI, Dominic; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). RAMASWAMY, Madhu; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). NEWCOMBE, Paul; AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB).

(74) Agent: ASTRAZENECA INTELLECTUAL PROPERTY; Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,

(54) Title: TREATMENT OF LUPUS NEPHRITIS WITH ANTI-TYPE I INF RECEPTOR ANTIBODY ANIFROLUMAB

Figure 6



(57) Abstract: The disclosure relates to methods and compositions for the treatment of lupus nephritis (LN) with anti-type I IFN receptor inhibitor antibody Anifrolumab. Results of clinical trials with intravenous and subcutaneous administration of Anifrolumab. Identification of markers for LN and delivery devices and pre-filled syringe for administration of Anifrolumab.

[Continued on next page]

KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*